Mitoquinone
- Generic Name
- Mitoquinone
- Drug Type
- Small Molecule
- Chemical Formula
- C37H44O4P
- CAS Number
- 444890-41-9
- Unique Ingredient Identifier
- 47BYS17IY0
- Background
Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease. Mitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. Clinical studies by the Parkinson's Study Group show that very high doses of an antioxidant called Coenzyme Q (which Mitoquinone effectively targets into mitochondria) appear to slow the progression of Parkinson's disease symptoms.
- Indication
Investigated for use/treatment in hepatitis (viral, C) and parkinson's disease.
ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments
- Conditions
- Amyotrophic Lateral Sclerosis ALS
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Duke University
- Target Recruit Count
- 50
- Registration Number
- NCT06429059
- Locations
- πΊπΈ
Temple University, Philadelphia, Pennsylvania, United States
πΊπΈDuke University Medical Center, Durham, North Carolina, United States
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
- Conditions
- Schizophrenia and Related DisordersCognitive ImpairmentMitochondrial Alteration
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06191965
- Locations
- πΊπΈ
McLean Hospital, Belmont, Massachusetts, United States
π¨πUniversity of Lausanne, Lausanne, Switzerland
πΊπΈYale School of Medicine, New Haven, Connecticut, United States
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
- Conditions
- FrailtyMild Cognitive ImpairmentAging
- Interventions
- Dietary Supplement: Placebo capsule
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 60
- Registration Number
- NCT06027554
- Locations
- πΊπΈ
UConn Health, Farmington, Connecticut, United States
Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 4
- Registration Number
- NCT05605548
- Locations
- πΊπΈ
Virginia Commonwealth University, Richmond, Virginia, United States
The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- D'Or Institute for Research and Education
- Target Recruit Count
- 44
- Registration Number
- NCT05146843
MitoQ for Fatigue in Multiple Sclerosis
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 9
- Registration Number
- NCT03166800
- Locations
- πΊπΈ
Oregon Health & Science University, Portland, Oregon, United States
The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- University of Colorado, Boulder
- Target Recruit Count
- 55
- Registration Number
- NCT02597023
- Locations
- πΊπΈ
Clinical Translational Research Center, Boulder, Colorado, United States
A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Antipodean Pharmaceuticals, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT01167088
- Locations
- π¬π§
Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Antipodean Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00433108
- Locations
- π³πΏ
New Zealand Liver Unit, Auckland City Hospital, Auckland, New Zealand
π³πΏWaikato Hospital, Hamilton, New Zealand
A Trial of MitoQ for the Treatment of People With Parkinson's Disease
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2010-07-21
- Lead Sponsor
- Antipodean Pharmaceuticals, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00329056
- Locations
- π¦πΊ
Austin Hospital, Melbourne, Victoria, Australia
π¦πΊWestmead Hospital, Sydney, New South Wales, Australia
π¦πΊThe Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.